1530 related articles for article (PubMed ID: 19296921)
1. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Hirsch EC; Hunot S
Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
[TBL] [Abstract][Full Text] [Related]
2. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
3. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
4. Neuroinflammation in Parkinson's disease.
Hirsch EC; Vyas S; Hunot S
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S210-2. PubMed ID: 22166438
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
6. Neuroinflammatory processes in Parkinson's disease.
Hirsch EC; Hunot S; Hartmann A
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S9-S15. PubMed ID: 15885630
[TBL] [Abstract][Full Text] [Related]
7. The role of glial reaction and inflammation in Parkinson's disease.
Hirsch EC; Breidert T; Rousselet E; Hunot S; Hartmann A; Michel PP
Ann N Y Acad Sci; 2003 Jun; 991():214-28. PubMed ID: 12846989
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease in the nuclear age of neuroinflammation.
Nolan YM; Sullivan AM; Toulouse A
Trends Mol Med; 2013 Mar; 19(3):187-96. PubMed ID: 23318001
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-inflammatory therapy for Parkinson's disease.
Gao HM; Liu B; Zhang W; Hong JS
Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
[TBL] [Abstract][Full Text] [Related]
10. Neuroinflammatory processes in Parkinson's disease.
Hunot S; Hirsch EC
Ann Neurol; 2003; 53 Suppl 3():S49-58; discussion S58-60. PubMed ID: 12666098
[TBL] [Abstract][Full Text] [Related]
11. [Future drug targets for Parkinson's disease].
Hirsch EC
Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
[TBL] [Abstract][Full Text] [Related]
12. Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's Disease.
Sita G; Hrelia P; Tarozzi A; Morroni F
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598127
[TBL] [Abstract][Full Text] [Related]
13. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
Collins LM; Toulouse A; Connor TJ; Nolan YM
Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
[TBL] [Abstract][Full Text] [Related]
14. Oxidative mechanisms in nigral cell death in Parkinson's disease.
Jenner P
Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
[TBL] [Abstract][Full Text] [Related]
15. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
Walsh S; Finn DP; Dowd E
Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
[TBL] [Abstract][Full Text] [Related]
16. Neuronal pathology in Parkinson's disease.
Schulz JB; Falkenburger BH
Cell Tissue Res; 2004 Oct; 318(1):135-47. PubMed ID: 15365812
[TBL] [Abstract][Full Text] [Related]
17. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.
Maia S; Arlicot N; Vierron E; Bodard S; Vergote J; Guilloteau D; Chalon S
Synapse; 2012 Jul; 66(7):573-83. PubMed ID: 22337286
[TBL] [Abstract][Full Text] [Related]
19. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
20. Modeling neuroinflammatory pathogenesis of Parkinson's disease.
Barnum CJ; Tansey MG
Prog Brain Res; 2010; 184():113-32. PubMed ID: 20887872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
